Jamil-ur-Rahman Center for Genome Research
The Jamil-ur-Rahman Center for Genome Research (JR-CGR) at the University of Karachi represents a transformative leap in genomic science and molecular medicine for Pakistan. Established through the generosity of Prof. Dr. Atta-ur-Rahman—a distinguished scientist, former Federal Minister for Science and Technology, and UNESCO Science Laureate—the center is a tribute to his father, Jamil-ur-Rahman, embodying a legacy of intellectual rigor and societal contribution. As part of the International Center for Chemical and Biological Sciences (ICCBS), a UNESCO and WHO-recognized Center of Excellence, the JR-CGR is positioned at the forefront of genomic innovation, addressing Pakistan’s unique healthcare challenges while fostering global scientific collaboration.
The center was founded to fill a critical gap in Pakistan’s scientific infrastructure, particularly in understanding population-specific genetic variations and their role in disease. Prof. Atta-ur-Rahman’s personal donation catalyzed its creation, integrating the JR-CGR within the International Center for Chemical and Biological Sciences (ICCBS). This strategic alignment enables the center to leverage existing expertise in medicinal chemistry, molecular biology and drug discovery while advancing a mission that bridges cutting-edge genomic research with clinical applications. Pakistan’s ethnically diverse population, with its distinct genetic makeup, offers invaluable insights into hereditary and polygenic disorders, yet prior to the JR-CGR, the nation lacked dedicated facilities for large-scale genomic studies. The center addresses this need by combining next-generation sequencing technologies, bioinformatics, and interdisciplinary collaboration to drive innovations in personalized medicine and public health.
Equipped with state-of-the-art infrastructure, including advanced DNA sequencers and high-throughput analytical systems, the JR-CGR has already embarked on pioneering initiatives despite its physical building being under construction. Early projects include sequencing genomes from Pakistani subpopulations to map genetic variations linked to diabetes, cardiovascular diseases, and cancer. These efforts are bolstered by synergies with ICCBS’s broader resources, such as the H.E.J. Research Institute of Chemistry, enabling translational research from genomic data generation to drug development.
The center’s research portfolio is anchored in three key areas: population genomics, infectious disease, and cancer. By studying Pakistan’s diverse ethnic groups, researchers have uncovered novel genetic variants associated with diseases like acute myeloid leukemia (AML), including recurrent mutations in the STAG2 and BCORL1 genes, which could refine treatment protocols. Collaborative work with global initiatives like the 1000 Genomes Project has enriched genomic databases with Pakistani-specific data, such as variants from the Punjabi Lahore (PJL) subpopulation, enhancing global understanding of South Asian genetics. In infectious disease research, the JR-CGR’s microbial genomics work tackles pressing public health issues, such as hospital-acquired infections, by decoding pathogen virulence and resistance mechanisms. Cancer genomics, another priority, includes studies on mutational profiles influenced by environmental toxins and pharmacogenomic research to optimize drug efficacy, such as analyzing the TP53 rs1042522 variant’s impact on chemotherapy outcomes in AML patients.
The center’s contributions extend directly to healthcare and public health policy. Its work on chemotherapy drug responses has informed tailored cancer treatments, addressing disparities in how imported therapies affect Pakistani populations. Genomic databases curated by the JR-CGR also underpin diagnostic tools and preventive strategies for hereditary disorders. During the COVID-19 pandemic, the center demonstrated agility by contributing to viral genome sequencing and serological studies, highlighting its role in pandemic preparedness.
Beyond research, the JR-CGR prioritizes capacity building to address Pakistan’s shortage of skilled genomic scientists and bioinformaticians. Through workshops like the National Workshop on Scientific Programming with Python and specialized training in forensic DNA analysis, the center cultivates local expertise. Partnerships with institutions such as Aga Khan University and Ziauddin University further amplify its impact, fostering interdisciplinary collaboration to ensure genomic advancements translate into clinical practice.
Looking to the future, the JR-CGR aims to expand its genomic datasets, integrate artificial intelligence for variant analysis, and strengthen global partnerships. Initiatives like the Sindh Forensic DNA and Serology Laboratory underscore its expanding role in legal medicine and population health. By maintaining Prof. Atta-ur-Rahman’s vision, the center continues to honor its namesake’s legacy while positioning Pakistan as a leader in genomic innovation.
In conclusion, the Jamil-ur-Rahman Center for Genome Research stands as a testament to visionary philanthropy and scientific ambition. By merging advanced research with education and public health engagement, it not only elevates Pakistan’s scientific stature but also paves the way for equitable access to precision medicine, ensuring that genomic discoveries benefit society at large.
The center was founded to fill a critical gap in Pakistan’s scientific infrastructure, particularly in understanding population-specific genetic variations and their role in disease. Prof. Atta-ur-Rahman’s personal donation catalyzed its creation, integrating the JR-CGR within the International Center for Chemical and Biological Sciences (ICCBS). This strategic alignment enables the center to leverage existing expertise in medicinal chemistry, molecular biology and drug discovery while advancing a mission that bridges cutting-edge genomic research with clinical applications. Pakistan’s ethnically diverse population, with its distinct genetic makeup, offers invaluable insights into hereditary and polygenic disorders, yet prior to the JR-CGR, the nation lacked dedicated facilities for large-scale genomic studies. The center addresses this need by combining next-generation sequencing technologies, bioinformatics, and interdisciplinary collaboration to drive innovations in personalized medicine and public health.
Equipped with state-of-the-art infrastructure, including advanced DNA sequencers and high-throughput analytical systems, the JR-CGR has already embarked on pioneering initiatives despite its physical building being under construction. Early projects include sequencing genomes from Pakistani subpopulations to map genetic variations linked to diabetes, cardiovascular diseases, and cancer. These efforts are bolstered by synergies with ICCBS’s broader resources, such as the H.E.J. Research Institute of Chemistry, enabling translational research from genomic data generation to drug development.
The center’s research portfolio is anchored in three key areas: population genomics, infectious disease, and cancer. By studying Pakistan’s diverse ethnic groups, researchers have uncovered novel genetic variants associated with diseases like acute myeloid leukemia (AML), including recurrent mutations in the STAG2 and BCORL1 genes, which could refine treatment protocols. Collaborative work with global initiatives like the 1000 Genomes Project has enriched genomic databases with Pakistani-specific data, such as variants from the Punjabi Lahore (PJL) subpopulation, enhancing global understanding of South Asian genetics. In infectious disease research, the JR-CGR’s microbial genomics work tackles pressing public health issues, such as hospital-acquired infections, by decoding pathogen virulence and resistance mechanisms. Cancer genomics, another priority, includes studies on mutational profiles influenced by environmental toxins and pharmacogenomic research to optimize drug efficacy, such as analyzing the TP53 rs1042522 variant’s impact on chemotherapy outcomes in AML patients.
The center’s contributions extend directly to healthcare and public health policy. Its work on chemotherapy drug responses has informed tailored cancer treatments, addressing disparities in how imported therapies affect Pakistani populations. Genomic databases curated by the JR-CGR also underpin diagnostic tools and preventive strategies for hereditary disorders. During the COVID-19 pandemic, the center demonstrated agility by contributing to viral genome sequencing and serological studies, highlighting its role in pandemic preparedness.
Beyond research, the JR-CGR prioritizes capacity building to address Pakistan’s shortage of skilled genomic scientists and bioinformaticians. Through workshops like the National Workshop on Scientific Programming with Python and specialized training in forensic DNA analysis, the center cultivates local expertise. Partnerships with institutions such as Aga Khan University and Ziauddin University further amplify its impact, fostering interdisciplinary collaboration to ensure genomic advancements translate into clinical practice.
Looking to the future, the JR-CGR aims to expand its genomic datasets, integrate artificial intelligence for variant analysis, and strengthen global partnerships. Initiatives like the Sindh Forensic DNA and Serology Laboratory underscore its expanding role in legal medicine and population health. By maintaining Prof. Atta-ur-Rahman’s vision, the center continues to honor its namesake’s legacy while positioning Pakistan as a leader in genomic innovation.
In conclusion, the Jamil-ur-Rahman Center for Genome Research stands as a testament to visionary philanthropy and scientific ambition. By merging advanced research with education and public health engagement, it not only elevates Pakistan’s scientific stature but also paves the way for equitable access to precision medicine, ensuring that genomic discoveries benefit society at large.